BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies

Broset, E. ; Pardo-Seco, J. ; Kanno, A.I. ; Aguilo, N. ; Dacosta, A.I. ; Rivero-Calle, I. ; Gonzalo-Asensio, J. (Universidad de Zaragoza) ; Locht, C. ; Leite, L.C.C. ; Martin, C. (Universidad de Zaragoza) ; Martinón-Torres, F.

Resumen: Background: The Bacillus Calmette-Guérin (BCG), the only vaccine against tuberculosis (TB) currently in use, has shown beneficial effects against unrelated infections and to enhance immune responses to vaccines. However, there is little evidence regarding the influence of BCG vaccination on pertussis. Methods: Here, we studied the ability of BCG to improve the immune responses to diphtheria, tetanus, and acellular (DTaP) or whole-cell pertussis (DTwP) vaccination in a mouse model. We included MTBVAC, an experimental live-attenuated vaccine derived from Mycobacterium tuberculosis, in our studies to explore if it presents similar heterologous immunity as BCG. Furthermore, we explored the potential effect of routine BCG vaccination on pertussis incidence worldwide. Findings: We found that both BCG and MTBVAC when administered before DTaP, triggered Th1 immune responses against diphtheria, tetanus, and pertussis in mice. Immunization with DTaP alone failed to trigger a Th1 response, as measured by the production of IFN-¿. Humoral responses against DTaP antigens were also enhanced by previous immunization with BCG or MTBVAC. Furthermore, exploration of human epidemiological data showed that pertussis incidence was 10-fold lower in countries that use DTaP and BCG compared to countries that use only DTaP. Interpretation: BCG vaccination may have a beneficial impact on the protection against pertussis conferred by DTaP. Further randomized controlled trials are needed to properly define the impact of BCG on pertussis incidence in a controlled setting. This could be a major finding that would support changes in immunization policies.

Idioma: Inglés

DOI: 10.1016/j.ebiom.2021.103254

Año: 2021

Publicado en: EBioMedicine 65 (2021), 103254 [12 pp.]
ISSN: 2352-3964

Factor impacto JCR: 11.205 (2021)

Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 14 / 139 = 0.101 (2021) - Q1 - T1

Factor impacto CITESCORE: 15.0 - Medicine (Q1) - Biochemistry, Genetics and Molecular Biology (Q1)

Factor impacto SCIMAGO: 2.663 - Medicine (miscellaneous) (Q1) - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA-FEDER/Construyendo Europa desde Aragón
Financiación: info:eu-repo/grantAgreement/EUR/EDCTP/RIA2016V-1637
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI16-01478
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI16-01569
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI07-0069
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI10-00540
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI19-01090
Financiación: info:eu-repo/grantAgreement/ES/MCIU/RTI2018-097625-B-I00
Financiación: info:eu-repo/grantAgreement/ES/MINECO/BES-2012-052937
Financiación: info:eu-repo/grantAgreement/ES/MINECO/BFU2015-72190-EXP

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)